Mohit Arora

Mohit Arora

Auto-generated profile, based on publicly available information

Mohit Arora

Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2022 in Bioscience Reports
Verified
Journal Article
Open access
PDF file
AKANURAG KUMAR
ANURAG KUMAR
VKVikas Kumar
Vikas Kumar
MAMohit Arora
Mohit Arora
MKManish Kumar
Manish Kumar
PAPrajwal Ammalli
Prajwal Ammalli
SCShyam Chauhan
Shyam Chauhan
Prothymosin-α (PTMA), a nuclear protein, is strikingly associated with unfavorable clinical outcomes in many cancers. However, no information about its clinical relevance in glioma was available. Therefore in the present study, we evaluated the prognostic utility of this protein in a cohort of 81 glioma patients. The PTMA expression was assessed by immunohistochemical analysis, quantitative PCR, and Western blotting. Furthermore, the association of PTMA with clinicopathological features and molecular alterations were assessed in the patient cohort and validated in multiomics datasets, The Cancer Genome Atlas (TCGA; n=667) and Chinese Glioma Genome Atlas (CGGA; n=1013). We observed an increase in PTMA expression with increasing histological grades of this malignancy. PTMA immunostaining also displayed a strong positive association with the MIB-1 index. Univariate analysis revealed a superior prognostic value of PTMA to predict overall survival (OS) as compared with the routinely used markers (p53, isocitrate dehydrogenase (IDH) 1 (IDH1), α-thalassemia/intellectual disability syndrome X-linked (ATRX), and Ki-67). Interestingly, in Cox regression analysis it emerged as an independent predictor of OS (hazard ratio (HR) = 13.71, 95% CI = 5.96–31.52, P<0.0001). Thus, our results demonstrate the potential prognostic utility of PTMA in glioma which may prove useful in the management of this deadly malignancy.

12 January 2024 in PNAS Nexus
Verified
Journal Article
Open access
PDF file
DEEPAK VERMADEEPAK VERMA
DEEPAK VERMA
SKShruti Kapoor
Shruti Kapoor
SKSarita Kumari
Sarita Kumari
DSDisha Sharma
Disha Sharma
JSJay Singh
Jay Singh
ACAnita Chopra
Anita Chopra
T-acute lymphoblastic leukemia (T-ALL) is a heterogeneous malignancy characterized by the abnormal proliferation of immature T-cell precursors. Despite advances in immunophenotypic classification, understanding the molecular landscape and its impact on patient prognosis remains challenging. In this study, we conducted comprehensive RNA sequencing in a cohort of 35 patients with T-ALL to unravel the intricate transcriptomic profile. Subsequently, we validated the prognostic relevance of 23 targets, encompassing (i) protein-coding genes—BAALC, HHEX, MEF2C, FAT1, LYL1, LMO2, LYN, and TAL1; (ii) epigenetic modifiers—DOT1L, EP300, EML4, RAG1, EZH2, and KDM6A; and (iii) long noncoding RNAs (lncRNAs)—XIST, PCAT18, PCAT14, LINC00202, LINC00461, LINC00648, ST20, MEF2C-AS1, and MALAT1 in an independent cohort of 99 patients with T-ALL. Principal component analysis revealed distinct clusters aligning with immunophenotypic subtypes, providing insights into the molecular heterogeneity of T-ALL. The identified signature genes exhibited associations with clinicopathologic features. Survival analysis uncovered several independent predictors of patient outcomes. Higher expression of MEF2C, BAALC, HHEX, and LYL1 genes emerged as robust indicators of poor overall survival (OS), event-free survival (EFS), and relapse-free survival (RFS). Higher LMO2 expression was correlated with adverse EFS and RFS outcomes. Intriguingly, increased expression of lncRNA ST20 coupled with RAG1 demonstrated a favorable prognostic impact on OS, EFS, and RFS. Conclusively, several hitherto unreported associations of gene expression patterns with clinicopathologic features and prognosis were identified, which may help understand T-ALL's molecular pathogenesis and provide prognostic markers.

11 January 2024 in Heliyon
Verified
Journal Article
Open access
AOAmobichukwu K. Ogbodo
Amobichukwu K. Ogbodo
DMDenis Mustafov
Denis Mustafov
MAMohit Arora
Mohit Arora
George I LambrouGeorge I Lambrou
George I Lambrou
MBMaria Braoudaki
Maria Braoudaki
Shoib Sarwar SiddiquiShoib Sarwar Siddiqui
Shoib Sarwar Siddiqui
Siglecs belong to a family of immune regulatory receptors predominantly found on hematopoietic cells. They interact with Sia, resulting in the activation or inhibition of the immune response. Previous reports have suggested that the SIGLEC12 gene, which encodes the Siglec-XII protein, is expressed in the epithelial tissues and upregulated in carcinomas. However, studies deciphering the role of Siglec-XII in renal cancer (RC) are still unavailable, and here we provide insights on this question. We conducted expression analysis using the Human Protein Atlas and UALCAN databases. The impact of SIGLEC12 on RC prognosis was determined using the KM plotter, and an assessment of immune infiltration with SIGLEC12 was performed using the TIMER database. GSEA was conducted to identify the pathways affected by SIGLEC12. Finally, using GeneMania, we identified Siglec-XII interacting proteins. Our findings indicated that macrophages express SIGLEC12 in the kidney. Furthermore, we hypothesize that Siglec-XII expression might be involved in the increase of primary RC, but this effect may not be dependent on the age of the patient. In the tumour microenvironment, oncogenic pathways appeared to be upregulated by SIGLEC12. Similarly, our analysis suggested that SIGLEC12-related kidney renal papillary cell carcinomas may be more suitable for targeted immunotherapy, such as CTLA-4 and PD-1/PD-L1 inhibitors. These preliminary results suggested that high expression of SIGLEC12 is associated with poor prognosis for RC. Future studies to assess its clinical utility are necessitated.

6 September 2023 in Bioscience Reports
Verified
Journal Article
Open access
PDF file
MAMohit Arora
Mohit Arora
SKSarita Kumari
Sarita Kumari
LKLokesh Kadian
Lokesh Kadian
GAGeethadevi Anupa
Geethadevi Anupa
JSJay Singh
Jay Singh
SCShyam Chauhan
Shyam Chauhan
Resistance to therapy in esophageal squamous cell carcinoma (ESCC) is a critical clinical problem and identification of novel therapeutic targets is highly warranted. Dipeptidyl peptidase III (DPP3) is a zinc-dependent aminopeptidase and functions in the terminal stages of the protein turnover. Several studies have reported overexpression and oncogenic functions of DPP3 in numerous malignancies. The present study aimed to determine the expression pattern and functional role of DPP3 in ESCC. DPP3 expression was assessed in normal and tumor tissues using quantitative real-time (qRT)-PCR and corroborated with ESCC gene expression datasets from Gene Expression Omnibus (GEO) and The cancer genome atlas (TCGA). DPP3 stable knockdown was performed in ESCC cells by shRNA and its effect on cell proliferation, migration, cell cycle, apoptosis, and activation of nuclear factor erythroid 2-related factor 2 (NRF2) pathway was assessed. The results suggested that DPP3 is overexpressed in ESCC and its knockdown leads to reduced proliferation, increased apoptosis, and inhibited migration of ESCC cells. Additionally, DPP3 knockdown leads to down-regulation of the NRF2 pathway proteins, such as NRF2, G6PD, and NQO1 along with increased sensitivity toward oxidative stress-induced cell death and chemotherapy. Conclusively, these results demonstrate critical role of DPP3 in ESCC and DPP3/NRF2 axis may serve as an attractive therapeutic target against chemoresistance in this malignancy.

1 September 2014 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
MAM. Arora
M. Arora
DESIGN: Aptamers are in vitro generated, short DNA and RNA sequences which are randomly created as a library. They are created with multiple permutations and combinations automatically within set primer ends. These are then exposed to the target structure against which we want an aptamer ‘selected’, using Sequential Enumeration of Ligands by Exponential enrichment (SELEX). Modified aptamers based on published sequences against glioma cell lines and newly generated sequences were used in the project to identify their binding targets. SUBJECTS: Commercially available glioma and glial cell lines were used along with in-house generated primary glioma cultures. METHODS: Cy3 and biotin- conjugated aptamers were incubated with live glioma cell cultures and imaged using confocal or light microscopy. This established proof of concept that the aptamers were binding to the glial cell more specifically than control. To determine the target ligand, aptamers were then reacted with glial cell lysate and subjected to precipitation using streptavidin agarose beads and SDS polyacrylamide gel electrophoresis. Proteins were then analysed by mass spectroscopy. RESULTS: Known and unknown aptamer protein ligands were co-precipitated. X ray cross complementing protein 6 (XRCC6 or Ku70) and x ray cross complementing protein 5 (XRCC5 or Ku80) were precipitated along with nucleolin and other related proteins. Heterogenous nuclear ribonuclear proteins or hnRNP's were also isolated. Ku70 and Ku80 were also precipitated in primary cell cultures. KU70 and Ku80 appear in the KEGG pathway and Non-homologus end joining pathway or NHEJ for DNA repair. CONCLUSIONS: The aptamer has shown preferential binding to glioma cells and could act as a delivery system for therapeutic payloads. The aptamer targets Ku70 and Ku80, which are known to be over expressed in other forms of cancer but their role in gliomagenesis has not been fully elucidated. Other novel proteins have also been identified. Thus the aptamer co-precipitation technique has identified potential glioma biomarkers that may be of clinical significance.